Core Viewpoint - The company reported a stable growth in operating revenue and a decrease in net profit attributable to shareholders by 25.64% compared to the same period last year, primarily due to reduced income from the transfer of drug agency rights and government subsidies [3]. Financial Performance - The company did not need to restate previous accounting data, indicating stability in financial reporting [3]. - The net profit attributable to shareholders decreased by 25.64% year-on-year, attributed to a reduction in income from non-recurring gains [3]. - The company reported a total asset impairment provision of 44.31 million yuan for the first three quarters of 2025, impacting the net profit by 37.50 million yuan [15][19]. Shareholder Information - The employee stock ownership plan held 6.7754 million shares, representing 0.56% of the total share capital as of the reporting period [10]. Corporate Governance - The company held its eighth board meeting and elected new board members and senior management on September 5, 2025, completing the board renewal process [11]. Subsidiary Developments - The company’s subsidiary received multiple drug registration approvals from the National Medical Products Administration, including for oral medications and injections, indicating ongoing product development and market expansion [6][7][8].

Core Viewpoint - Yifan Pharmaceutical announced that its wholly-owned subsidiary Hefei Yifan Biopharmaceutical Co., Ltd. received the drug registration certificate for injectable isavuconazole from the National Medical Products Administration on September 15, 2025 [2] Group 1 - The drug registration certificate is a significant regulatory milestone for the company, indicating approval for the injectable formulation of isavuconazole [2] - This approval may enhance the company's product portfolio and market presence in the pharmaceutical industry [2] - The announcement reflects the company's ongoing commitment to developing innovative treatments and expanding its offerings in the biopharmaceutical sector [2]

Core Viewpoint - Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., received the drug registration certificate for injectable isavuconazole from the National Medical Products Administration on September 15, 2025. This drug is an anti-infective medication used for treating adult patients with invasive aspergillosis and invasive mucormycosis [1]. Company Summary - Yifan Pharmaceutical's subsidiary, Hefei Yifan Biopharmaceutical, has been granted approval for injectable isavuconazole, indicating a significant milestone in expanding its product portfolio in the anti-infective segment [1]. - The approval of injectable isavuconazole positions the company to address critical medical needs in treating serious fungal infections, potentially enhancing its market presence and revenue streams [1]. Industry Summary - The approval of injectable isavuconazole reflects ongoing advancements in the pharmaceutical industry, particularly in the development of treatments for invasive fungal infections, which are increasingly recognized as significant health threats [1]. - The introduction of new anti-infective drugs like isavuconazole is crucial for improving patient outcomes and addressing the growing concerns over fungal infections in immunocompromised populations [1].

Core Viewpoint - The company announced that its wholly-owned subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the injection of Sulfate Isavuconazole, which is an anti-infection drug used for treating invasive fungal infections in adults [1] Company Summary - The injection of Sulfate Isavuconazole is specifically indicated for the treatment of invasive aspergillosis and invasive mucormycosis [1] - As of the date of the report, a total of 9 companies in China have received approval for the injection of Sulfate Isavuconazole, with several others undergoing review for generic drug applications [1] - The company has invested approximately 7.8972 million yuan in the research and development of Sulfate Isavuconazole [1]

Core Viewpoint - The company has received approval for its injectable drug, Isavuconazole sulfate, from the National Medical Products Administration, marking a significant milestone in its product portfolio [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., received the drug registration certificate for injectable Isavuconazole sulfate on September 15, 2025 [1] - Isavuconazole sulfate is an anti-infective medication indicated for the treatment of invasive aspergillosis and invasive mucormycosis in adult patients [1]

Core Viewpoint - The company received approval for its injectable drug Isavuconazole from the National Medical Products Administration, marking a significant milestone in its product portfolio [1] Company Summary - Yifan Pharmaceutical's wholly-owned subsidiary Hefei Yifan Biopharmaceutical Co., Ltd. obtained the drug registration certificate for injectable Isavuconazole on September 15, 2025 [1] - Isavuconazole is an antifungal medication indicated for the treatment of invasive infections in adult patients, specifically invasive aspergillosis and invasive mucormycosis [1]

Group 1 - The core point of the article is that Yifan Pharmaceutical (002019) announced the approval of its subsidiary Hefei Yifan Biopharmaceutical Co., Ltd. for the injection of Sulfate Isavuconazole by the National Medical Products Administration [1] - The approved drug, Sulfate Isavuconazole, is an anti-infective medication [1] - It is indicated for the treatment of adult patients with invasive fungal infections, specifically invasive aspergillosis and invasive mucormycosis [1]

Group 1 - Huazhong Securities has been approved to issue subordinate corporate bonds with a total face value of no more than 10 billion yuan [1] - Jinbei Automotive plans to invest 240 million yuan to establish an automotive industry investment fund focusing on electrification, intelligence, and low carbon [1] - Linyang Energy is expected to win a bid for a 244 million yuan metering equipment project from Southern Power Grid [1][2] Group 2 - Renfu Pharmaceutical's subsidiary has received drug registration certificates for two products, including a medication for acute hypotension [3][4] - Nanjing Steel plans to distribute a cash dividend of 0.1186 yuan per share [5][6] - Pairui Co. has signed a strategic cooperation agreement with Xi'an Power Electronics Research Institute to develop power devices [7][8] Group 3 - Haixing Electric is expected to win a bid for a 214 million yuan metering equipment project from Southern Power Grid [9][10] - Kuangda Technology is planning a change in control, leading to a continued suspension of its stock [11][12] - Samsung Medical is expected to win a bid for a 274 million yuan metering equipment project from Southern Power Grid [13][14] Group 4 - Jiukang Bio has obtained a medical device registration certificate for a specific diagnostic kit [15][16] - Hechuan Technology's minority shareholder plans to transfer a 13% stake in a subsidiary [17][18] - DiAo Micro has launched a new eUSB2 repeater product for various electronic applications [19][20] Group 5 - David Medical's electric surgical table registration application has been accepted [21][22] - Hangxin Technology plans to apply for a total of 280 million yuan in bank credit [23][24] - Liyuan Technology's non-independent director has resigned [25][26] Group 6 - Ningbo Construction's subsidiary has won a construction project bid worth 729 million yuan [27][28] - Huaren Pharmaceutical's subsidiary has received approval for a raw material drug [29][30] - Suwen Electric plans to distribute a cash dividend of 1 yuan per 10 shares [31][32] Group 7 - Solar Energy has received 1.692 billion yuan in renewable energy subsidies [33][34] - Wangli Security has obtained a patent for a new lock structure [35][36] - Zhejiang Energy's vice chairman has resigned due to age reasons [37][38] Group 8 - Beilu Pharmaceutical's subsidiary has passed GMP certification in Brazil [39][40] - Zhejiang Communications has a subsidiary that is expected to win a highway project bid [41][42] - Xinzhi Group has received a government subsidy of 11.1978 million yuan [43][44] Group 9 - Dong'an Power's engine sales in August increased by 3.44% year-on-year [45][46] - Baiyun Mountain's subsidiary has passed the consistency evaluation for two generic drugs [47][48] - Yipin Hong's subsidiary has received a drug registration certificate for a specific injection [49][50] Group 10 - Far East Holdings' subsidiary has won multiple contracts totaling 1.689 billion yuan [51][52] - Good Housekeeping's shareholder plans to reduce holdings by up to 3.5 million shares [53][54] - Guanghong Technology's shareholders have set a transfer price of 23.33 yuan per share [55][56] Group 11 - Keli Sensor plans to acquire 45% of Huahong Technology's shares for 122 million yuan [57][58] - Jianmin Group's furosemide oral solution has been approved for market launch [59][60] - Jinghua Laser's directors plan to reduce their holdings by up to 143,420 shares [61][62] Group 12 - Zhuyue Group is planning a share transfer that will change its controlling shareholder [63][64] - Terid has pre-bid for two projects totaling approximately 698 million yuan [65][66] - Zhonghuan Hailu is planning a change in control, leading to a continued suspension of its stock and convertible bonds [67][68] Group 13 - Great Wall Motors reported August sales of 115,600 vehicles, a year-on-year increase of 22.33% [69][70] - Guizhou Tire's controlling shareholder has committed not to reduce holdings for 12 months [71][72] - San Da Membrane's shareholder plans to reduce holdings by up to 1% of the company's shares [73][74] Group 14 - Chint Electric has decided to terminate the spin-off of its subsidiary for listing [75][76] - Jusaylong's shareholder plans to reduce holdings by up to 1% of the company's shares [77][78]

Core Viewpoint - The company Yipinhong (300723.SZ) has received approval from the National Medical Products Administration for the injection of Sulfate Isavuconazole, indicating a significant advancement in its product portfolio and potential market impact [1] Company Summary - Yipinhong's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has been granted a drug registration certificate for injectable Sulfate Isavuconazole [1] - The approved injectable Sulfate Isavuconazole is classified as a Category 4 chemical drug and has passed the consistency evaluation [1] Product Details - Injectable Sulfate Isavuconazole is indicated for the treatment of adult patients with invasive fungal infections, specifically invasive aspergillosis and invasive mucormycosis [1] - The product is categorized as a Class B product under the national medical insurance scheme [1] Market Potential - According to data from Minet, the sales scale of injectable Sulfate Isavuconazole in urban and county-level public hospitals in China is projected to be approximately 225.05 million RMB in 2024 [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the injection of Sulfate Isavuconazole, marking a significant step in enhancing its product pipeline and competitiveness in the anti-infection sector [1] Company Summary - The company's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has obtained the drug registration certificate for injectable Sulfate Isavuconazole [1] - The approved indication for injectable Sulfate Isavuconazole is primarily for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis [1] - This approval allows the company to sell this specific drug in the domestic market, thereby enriching its product offerings [1]